Mariner’s Neumora Therapeutics NMRA Stock Holding History

Mariner’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-92,689	Closed	-$92.7K	–	3618
2025 Q1	$92.7K	Buy	+92,689	New	+$159K	﹤0.01%	3203

Other funds holding NMRA

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Mariner's NMRA Position: Q2 2025 in Review

Mariner sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 92,689 shares — an estimated $92.7K sold.

Mariner first reported a position in NMRA in Q1 2025 and held it in 1 quarter. The position peaked at $92.7K in Q1 2025. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

Mariner reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
Mariner sold 92,689 Neumora Therapeutics shares in Q2 2025, an estimated $92.7K.
Mariner first reported a position in Neumora Therapeutics in Q1 2025 and held it in 1 quarter.
Mariner's Neumora Therapeutics position peaked at $92.7K in Q1 2025.
98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on Mariner's 13F filing for Q2 2025, filed 14 Aug 2025.